Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.

Regeneron Pharmaceuticals ... Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in …

Regeneron is a leading biotechnology company dedicated to inventing, developing and commercializing life-transforming medicines for people with serious diseases.

Asia EMEA North America Working at Regeneron We are a team of original thinkers who work together to create life-transforming medicines for people with serious diseases. Whether it's in …

Oct 28, 2025 · After an FDA rejection for high-dose (HD) Eylea, Regeneron said that it is making progress in its efforts to secure alternate manufacturing help.

6 days ago · By Tina Traster Tarrytown-based Regeneron Pharmaceuticals, which bought 1 Avon Place in Suffern for $38.9 million in Dec. 2023, had planned to use the facility for research, …

Oct 29, 2025 · FDA rejects Regeneron’s Eylea HD amid filling facility woes Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.

Oct 28, 2025 · Regeneron stock advanced early Tuesday on better-than-expected third-quarter earnings despite a big tax hit.

Oct 31, 2025 · We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center ® and pioneering genetic medicine platforms, enabling us to …

Oct 29, 2025 · Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end …